The Global Regenerative Medicine Market will Reach $6.4Bn in 2014

Monday 6 January 2014, Amsterdam

A new report calculates the global regenerative medicine market will reach $4.6bn in 2014 and revenues will show strong growth to 2024. These revenue forecasts and others appear in the latest report Translational Regenerative Medicine: World Market Prospects 2014-2024 .

Regenerative medicine promises to one day provide cures for major diseases such as cancer, heart disease and diabetes, as well as a limitless supply of organs for transplantation. This exciting field covers therapies that restore the function of the human body – at the level of cells, tissues and organs – through technologies such as stem cells, tissue engineering and gene therapy. Although the regenerative medicine market is at an early stage of development, it is expected to grow strongly throughout 2014-2024, driven by the commercial success of current regenerative therapies, advances in technology, improvements in regulation, and rapid commercialisation of products in the emerging markets of the Asia-Pacific.

Thomas Ling, a pharmaceutical and medical devices industry analyst, observes: “Regenerative medicine retains its potential for accelerated growth during 2014-2024. The commercial success of regenerative therapies such as Apligraf and Dermagraft has shown that there is a route to market. Advances in the basic science, such as induced pluripotent stem cells, and technological developments such as 3D bioprinting, will extend the range of possible therapeutic applications and may provide solutions to the problem of scaling up the manufacturing of cell and tissue therapies. Glybera, the first gene therapy to be approved in Europe, represents another milestone that shows how far translational regenerative medicine has come. Taking advantage of the opportunities in this fast-moving market will require companies to understand the distinctive features of the industry and navigate challenges such as the availability of venture capital, the evolving patent landscape and the process of obtaining reimbursement for regenerative therapies.”

The US is currently the leading regional market, however, In time, supported by government initiatives and more rapid translation of research into commercial products, the emerging economies of the Asia-Pacific are predicted to overtake Europe as the second-largest regional market.

The new report provides revenue forecasts to 2024 for the world translational regenerative medicine market and leading regional markets. It forecasts sales in the US, Europe, and Asia-Pacific markets. The report also forecasts sales for the market segments of stem cell therapies, tissue engineered products and gene therapies. It includes interviews with industry experts regarding current market trends.